CA3159064A1 — Treatment of circadian rhythm disorders
Assigned to Vanda Pharmaceuticals Inc · Expires 2013-08-01 · 13y expired
What this patent protects
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. Embodiments of the invention rel…
USPTO Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. Embodiments of the invention relate to the use of tasimelteon for treatment of a circadian rhythm disorder in a patient who is being treated with a beta-adrenergic receptor antagonist, wherein: a 50 mg or 100mg dose of tasimelteon is to be administered to the patient once daily before bedtime.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.